Percentages of children and pregnant women who have received recommended vaccines, by target population and vaccine/antigen covering results from the 2011, 2013, 2015, 2017, 2019, and 2021 cycles of the Childhood National Immunization Coverage Survey.

**Effective November 14, 2024 this page will no longer be updated. Information about COVID-19 and other respiratory viruses is available on Public Health Ontario’s interactive respiratory virus tool: https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/Respiratory-Virus-Tool ** As of January 26, 2023, the population counts are based on Statistics Canada’s 2021 estimates. The coverage methodology has been revised to calculate age based on the current date and deceased individuals are no longer included. The method used to count daily dose administrations has changed is now based on the date delivered versus the day entered into the data system. Historical data has been updated. Please note that Cases by Vaccination Status data will no longer be published as of June 30, 2022. Please note that case rates by vaccination status and age group data will no longer be published as of July 13, 2022. Please note that Hospitalization by Vaccination Status data will no longer be published as of June 30, 2022. Learn more about COVID-19 vaccines. ##Data includes: * daily and total doses administered * individuals with at least one dose * individuals fully vaccinated * total doses given to fully vaccinated individuals * vaccinations by age * percentage of age group * individuals with at least one dose, by PHU, by age group * individuals fully vaccinated, by PHU, by age group * COVID-19 cases by status: not fully vaccinated, fully vaccinated, vaccinated with booster * individuals in hospital due to COVID-19 (excluding ICU) by status: unvaccinated, partially vaccinated, fully vaccinated * individuals in ICU due to COVID-19 by status: unvaccinated, partially vaccinated, fully vaccinated, unknown * rate of COVID-19 cases per 100,000 by status and age group * rate per 100,000 (7-day average) by status and age group All data reflects totals from 8 p.m. the previous day. This dataset is subject to change. Additional notes * Data entry of vaccination records is still in progress, therefore the dosage data may not be a full representation of all vaccination doses administered in Ontario. * The data does not include dosage data where consent was not provided for vaccination records to be entered into the provincial CoVax system. This includes individual records as well as records from some Indigenous communities where those communities have not consented to including vaccination information into CoVax. ##Hospitalizations and cases by vaccination status Hospitalizations * This is a new data collection and the data quality will continue to improve as hospitals continue to submit data. * In order to understand the vaccination status of patients currently hospitalized, a new data collection process was developed and this may cause discrepancies between other hospitalization numbers being collected using a different data collection process. * Data on patients in ICU are being collected from two different data sources with different extraction times and public reporting cycles. The existing data source (Critical Care Information System, CCIS) does not have vaccination status. * Historical data for hospitalizations by region may change over time as hospitals update previously entered data. * Due to incomplete weekend and holiday reporting, vaccination status data for hospital and ICU admissions is not updated on Sundays, Mondays and the day after holidays * Unvaccinated is defined as not having any dose, or between 0-13 days after administration of the first dose of a COVID-19 vaccine. * Partially vaccinated is defined as 14 days or more after the first dose of a 2-dose series COVID-19 vaccine, or between 0-13 days after administration of the second dose * Fully vaccinated is defined as 14 days or more after receipt of the second dose of a 2-dose series COVID-19 vaccine Cases * The cases by vaccination status may not match the daily COVID-19 case count because records with a missing or invalid health card number cannot be linked.

As of September 25, 2022, there have been around 10,800 confirmed deaths due to COVID-19 among unvaccinated Canadians since the start of the national vaccination campaign in December 2020. In contrast, just 3,821 (16.8%) COVID-19 deaths were reported among those who were fully vaccinated during the same time period. This statistic illustrates the number of confirmed COVID-19 deaths in Canada from December 14, 2020 to September 25, 2022, by vaccination status.

This dataset reports the daily reported number of the 7-day moving average rates of Deaths involving COVID-19 by vaccination status and by age group. Learn how the Government of Ontario is helping to keep Ontarians safe during the 2019 Novel Coronavirus outbreak. Effective November 14, 2024 this page will no longer be updated. Information about COVID-19 and other respiratory viruses is available on Public Health Ontario’s interactive respiratory virus tool: https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/Respiratory-Virus-Tool Data includes: * Date on which the death occurred * Age group * 7-day moving average of the last seven days of the death rate per 100,000 for those not fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those vaccinated with at least one booster ##Additional notes As of June 16, all COVID-19 datasets will be updated weekly on Thursdays by 2pm. As of January 12, 2024, data from the date of January 1, 2024 onwards reflect updated population estimates. This update specifically impacts data for the 'not fully vaccinated' category. On November 30, 2023 the count of COVID-19 deaths was updated to include missing historical deaths from January 15, 2020 to March 31, 2023. CCM is a dynamic disease reporting system which allows ongoing update to data previously entered. As a result, data extracted from CCM represents a snapshot at the time of extraction and may differ from previous or subsequent results. Public Health Units continually clean up COVID-19 data, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes and current totals being different from previously reported cases and deaths. Observed trends over time should be interpreted with caution for the most recent period due to reporting and/or data entry lags. The data does not include vaccination data for people who did not provide consent for vaccination records to be entered into the provincial COVaxON system. This includes individual records as well as records from some Indigenous communities where those communities have not consented to including vaccination information in COVaxON. “Not fully vaccinated” category includes people with no vaccine and one dose of double-dose vaccine. “People with one dose of double-dose vaccine” category has a small and constantly changing number. The combination will stabilize the results. Spikes, negative numbers and other data anomalies: Due to ongoing data entry and data quality assurance activities in Case and Contact Management system (CCM) file, Public Health Units continually clean up COVID-19, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes, negative numbers and current totals being different from previously reported case and death counts. Public Health Units report cause of death in the CCM based on information available to them at the time of reporting and in accordance with definitions provided by Public Health Ontario. The medical certificate of death is the official record and the cause of death could be different. Deaths are defined per the outcome field in CCM marked as “Fatal”. Deaths in COVID-19 cases identified as unrelated to COVID-19 are not included in the Deaths involving COVID-19 reported. Rates for the most recent days are subject to reporting lags All data reflects totals from 8 p.m. the previous day. This dataset is subject to change.

Number and percentage of persons who reported having their last influenza immunization in the past 12 months, by age group and sex.

Snapshot img

Vaccines Market Size 2025-2029

The vaccines market size is forecast to increase by USD 193.7 billion at a CAGR of 23% between 2024 and 2029.

The market is experiencing robust growth, driven by several key factors. Increased funding for vaccine development and the launch of new vaccines are major catalysts, particularly for chronic infections where novel solutions are in high demand. Another significant trend is the increasing use of adjuvants in vaccines, which enhance their efficacy and broaden their application. These developments reflect the market's response to the growing demand for advanced, innovative solutions. Moreover, advancements in medical technology and changing consumer preferences are shaping the market landscape. There is a transition towards more efficient systems, better accessibility, and higher industry standards. 
The vaccine market's future growth is underpinned by these drivers, which continue to influence its direction. As the market evolves, efforts to meet the growing demand for advanced solutions are expanding its scope, ensuring long-term growth. The industry's focus on delivering innovative, effective vaccines is a testament to its commitment to addressing global health challenges posed by infectious diseases and improving overall public health.

What will be the size of the market during the forecast period?

Request Free Sample

Vaccines Market Segmentation

The vaccines market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019 - 2023 for the following segments.TypeHuman vaccineAnimal vaccineEnd-userHospitalsClinicsRoute of AdministrationOralParenteralNasalOralParenteralNasalAge GroupPediatricAdultPediatricAdultTechnologyConjugateRecombinantLive AttenuatedOthersDiseaseViralBacterialParasiticOthersGeographyNorth AmericaUSCanadaEuropeFranceGermanyRussiaUKAsiaRest of World (ROW)

Which is the largest segment driving market growth?

The human vaccine segment is estimated to witness significant growth during the forecast period. The human market encompasses a vast array of products designed to prevent infectious diseases and foster global health. These vaccines function by stimulating the immune system to respond to specific pathogens, thereby conferring immunity against various diseases. Human vaccines can be classified into several types based on their composition, mechanism of action, and target population. One significant category is inactivated or killed vaccines, which utilize heat, chemicals, or radiation to render pathogens non-infectious. Examples include the inactivated polio vaccine (IPV) and influenza vaccine. These vaccines offer increased safety for individuals with compromised immune systems but may necessitate multiple doses to achieve adequate immunity.

Other types of human vaccines include therapeutic vaccines, conjugate vaccines, recombinant vaccines, live attenuated vaccines, toxoid vaccines, and subunit vaccines. These vaccines play a pivotal role in protecting billions of people from diseases and promoting overall health.

Get a glance at the market share of various regions. Download the PDF Sample

The Human vaccine segment was valued at USD 57.40 billion in 2019 and showed a gradual increase during the forecast period.

Advancements in vaccine development are being driven by cutting-edge technologies such as nanoparticle vaccines and mRNA platforms, which enable highly targeted immune responses. The incorporation of adjuvant systems and immune modulators enhances vaccine efficacy, while viral vectors, DNA vaccines, and synthetic peptides offer diverse strategies for antigen design. Needle-free delivery methods, such as microneedle patches, are improving patient comfort and access, with the potential to revolutionize immunization tech. Innovations in cold chain technology and smart packaging, paired with digital tracking and blockchain records, ensure the safe transport and storage of vaccines. AI diagnostics and machine learning-driven predictive models are accelerating the development and evaluation of vaccines, while bioengineering tools enable precision dosing and rapid production. In addition, recombinant proteins, conjugate systems, and live attenuated or toxoid formulas continue to offer robust options for therapeutic vaccines. The use of sustainable materials and eco-friendly vials further reflects the growing focus on environmentally conscious practices in vaccine production. Data analytics are playing a pivotal role in optimizing vaccine delivery and monitoring outcomes.

Which region is leading the market?

North America is estimated to contribute 39% to the growth of the global market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

Technavio's analysts have elaborately explained the regio

Canada Imports from Romania of Human or Animal Blood, Antisera and Other Blood Fractions, Vaccines, Toxins was US$40 during 2023, according to the United Nations COMTRADE database on international trade.

BackgroundTo identify determinants influencing Canadian parents’ decision not to vaccinate their children aged 6 months to 17 years against seasonal influenza.MethodsData from the 2022 Childhood COVID-19 Immunization Coverage Survey, a national survey of approximately 10,500 Canadian parents/guardians and their children, was analyzed. The survey examined influenza vaccine coverage, parental perspectives on vaccines, reasons for hesitancy, and factors influencing immunization. Socio-demographic characteristics, including ethnicity, household income, working sector, educational attainment, and prevalence of chronic medical conditions among children were considered. Historical vaccine uptake and the impact of the COVID-19 pandemic on immunization decisions were also reviewed. Key determinants of non-vaccination in the 2021–2022 influenza season were analyzed using multivariable logistic regression, with a statistical significance level set at p-value

This table presents a series of indicators relating to the COVID-19 pandemic, including relating to perceptions of Canadians' mental health, precautions they've taken, and willingness to receive vaccine. Estimates are based on preliminary monthly data from the Canadian Community Health Survey, and are provided for the Canadian population aged 12 and older excluding the territories, by gender, age and region of residence.

Snapshot img

Human Combination Vaccines Market Size 2024-2028

The human combination vaccines market size is forecast to increase by USD 7.03 billion at a CAGR of 8.69% between 2023 and 2028.

The market is experiencing significant growth due to several key trends and challenges. One of the primary drivers is the increasing antiviral drug resistance, which has led to a greater emphasis on preventive measures through vaccines. Additionally, the threat from bioterrorism has heightened the need for effective combination vaccines to protect against multiple diseases simultaneously. Vaccine distribution challenges, such as vaccine refrigeration and packaging, are significant considerations in the market. Furthermore, the consolidation of different immunization schedules is streamlining vaccine administration and increasing convenience for healthcare providers and patients. These trends are shaping the market and are expected to continue driving growth In the coming years.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The market encompasses the production and distribution of vaccines that protect against multiple diseases with a single administration. This market is driven by the newborn population growth and the ongoing need for pediatric immunization. Inactivated virus vaccines and live attenuated vaccines are the primary types of combination vaccines, each offering unique advantages in terms of vaccine safety, effectiveness, and ease of administration. Immunization coverage rates vary globally, with ongoing efforts to increase vaccination adoption and combat vaccine resistance. The threat of bioterrorism and emerging infectious diseases further underscores the importance of vaccine development and immunization campaigns.
The global vaccine market is experiencing steady growth, fueled by advancements in vaccine technology, including pathogen inactivation and multi-dose vaccine administration. Vaccine compliance remains a crucial factor, with ongoing initiatives to improve vaccine safety, effectiveness, and vaccine compliance. The vaccine supply chain is a critical component of the market, with ongoing efforts to ensure a reliable and efficient distribution network. Disease prevention remains the primary focus of the market, with ongoing research and development aimed at addressing vaccine resistance and emerging diseases. The market is expected to continue growing, driven by the need to protect global populations from infectious diseases and ensure public health and safety.

How is this Industry segmented and which is the largest segment?

The industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  Inactivated vaccine
  Live attenuated vaccine


Channel

  Hospitals
  Retailers
  Online


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    Japan


  Rest of World (ROW)

By Type Insights

The inactivated vaccine segment is estimated to witness significant growth during the forecast period.The inactivated segment dominates The market due to its superior tolerability and fewer complications when multiple antigens are used. Inactivated human combination vaccines, such as those for Chickenpox, DTaP, IPV, Pediarix, Pentacel, and Tetraxim, are preferred due to their ability to provide comprehensive protection against various diseases. However, producing these vaccines poses challenges due to potential antigen incompatibilities and interactions among ingredients. Inactivated vaccines are developed using pathogen particles that have been destroyed or killed, ensuring a strong immune response against the targeted organisms. Medical practitioners prioritize these vaccines due to their effectiveness in preventing diseases, including Diphtheria, Tetanus, Acellular pertussis, Polio, and Hib.

Get a glance at the market report of share of various segments Request Free Sample

The inactivated vaccine segment was valued at USD 8.8 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 44% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market size of various regions, Request Free Sample

The North American market holds the largest share in 2023, driven by stringent regulatory policies mandating infant vaccination. Despite a slower growth rate due to decreasing infectious disease prevalence, the market expansion is fueled by ongoing initiatives to promote vaccine usage. In other regions, the market is driven by the rising incidence of di

Canada Imports from Belarus of Human or Animal Blood, Antisera and Other Blood Fractions, Vaccines, Toxins was US$188 during 2022, according to the United Nations COMTRADE database on international trade.

This dataset reports the daily reported number of the 7-day moving average rates of Deaths involving COVID-19 by vaccination status and by age group. Learn how the Government of Ontario is helping to keep Ontarians safe during the 2019 Novel Coronavirus outbreak. Data includes: * Date on which the death occurred * Age group * 7-day moving average of the last seven days of the death rate per 100,000 for those not fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those vaccinated with at least one booster ##Additional notes As of June 16, all COVID-19 datasets will be updated weekly on Thursdays by 2pm. As of January 12, 2024, data from the date of January 1, 2024 onwards reflect updated population estimates. This update specifically impacts data for the 'not fully vaccinated' category. On November 30, 2023 the count of COVID-19 deaths was updated to include missing historical deaths from January 15, 2020 to March 31, 2023. CCM is a dynamic disease reporting system which allows ongoing update to data previously entered. As a result, data extracted from CCM represents a snapshot at the time of extraction and may differ from previous or subsequent results. Public Health Units continually clean up COVID-19 data, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes and current totals being different from previously reported cases and deaths. Observed trends over time should be interpreted with caution for the most recent period due to reporting and/or data entry lags. The data does not include vaccination data for people who did not provide consent for vaccination records to be entered into the provincial COVaxON system. This includes individual records as well as records from some Indigenous communities where those communities have not consented to including vaccination information in COVaxON. “Not fully vaccinated” category includes people with no vaccine and one dose of double-dose vaccine. “People with one dose of double-dose vaccine” category has a small and constantly changing number. The combination will stabilize the results. Spikes, negative numbers and other data anomalies: Due to ongoing data entry and data quality assurance activities in Case and Contact Management system (CCM) file, Public Health Units continually clean up COVID-19, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes, negative numbers and current totals being different from previously reported case and death counts. Public Health Units report cause of death in the CCM based on information available to them at the time of reporting and in accordance with definitions provided by Public Health Ontario. The medical certificate of death is the official record and the cause of death could be different. Deaths are defined per the outcome field in CCM marked as “Fatal”. Deaths in COVID-19 cases identified as unrelated to COVID-19 are not included in the Deaths involving COVID-19 reported. Rates for the most recent days are subject to reporting lags All data reflects totals from 8 p.m. the previous day. This dataset is subject to change.

Snapshot img

Vaccine Research Market Size 2024-2028

The vaccine research market size is forecast to increase by USD 21.4 billion at a CAGR of 10.84% between 2023 and 2028. The market is witnessing substantial growth due to the persistently high prevalence of infectious diseases and the requirement for innovative vaccines to address chronic infections. Additionally, the advancement of adjuvants and vaccine delivery systems is significantly contributing to market expansion. This growth is driven by the increasing demand for efficient, accessible, and high-standard solutions. Companies in this sector are adapting their strategies to align with these trends, focusing on sustainability and operational efficiency to remain competitive. The market's future direction is influenced by these key drivers, ensuring its continued growth and evolution. As the industry progresses, the demand for advanced solutions continues to expand its scope.

What will be the size of the Vaccine Research Market during the forecast period?

Request Free Vaccine Research Market Sample

Vaccine Research Market Segmentation

The Vaccine Research market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

End-user

  Public
  Private


Age Group

  Pediatric
  Adult


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

Which is the largest segment driving market growth?

The public segment is estimated to witness significant growth during the forecast period.

Government entities, including the US National Institute of Allergy and Infectious Diseases (NIAID) and the US National Institutes of Health (NIH), play a significant role in vaccine research. In response to the COVID-19 pandemic, governments worldwide have made substantial investments in vaccine development, from basic science and pre-clinical stages through clinical trials. These efforts led to the creation of several effective COVID-19 vaccines. Governments have been instrumental in funding and supporting each phase of the vaccine development process. Immunization programs focus on various diseases, such as pneumococcal disease, measles, mumps, mono, and varicella, diphtheria, tetanus, HPV, MMR, rotavirus, influenza, hepatitis, typhoid, meningococcal, rabies, Japanese encephalitis, yellow fever, and polio.

Vaccines come in various forms, including injectable, oral, and nasal, and are produced by vaccine manufacturers, genomic research centers, academic institutions, and private laboratories. They are used in hospital settings, clinics, and pharmacies. Vaccines protect against microorganisms, toxins, and surface proteins, enhancing the immune system's response to pathogens. Vaccine research continues to address physiological disorders, allergies, cancer, and infectious diseases, such as hypertension, dyslipidemia, Alzheimer's, inflammatory diseases, and self-antigens. Vaccines are available as combination vaccines, monovaccines, subunit, recombinant, polysaccharide, live-attenuated vaccines, inactivated vaccines, and DNA vaccines. Vaccines are crucial components of preventive healthcare and public health initiatives, reducing morbidity and mortality.

Get a glance at the market share of various regions. Download the PDF Sample

The Public segment was valued at USD 12.10 billion in 2018 and showed a gradual increase during the forecast period.

Which region is leading the market?

North America is estimated to contribute 44% to the growth of the global Vaccine Research market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.The market in North America is significantly driven by the high prevalence of both infectious and non-infectious diseases. In the US, influenza, hepatitis A, hepatitis B, HIV, measles, malaria, tuberculosis, and cancer are among the most common health concerns. The prevalence of these diseases continues to increase, particularly in developed countries. For instance, influenza cases peak annually in the US during November to February. Although vaccines have led to a decline in diseases like mumps, measles, and rubella (MMR), they have not been eradicated completely. Vaccine research focuses on various types, including conjugate, recombinant, live attenuated, toxoid, and inactivated vaccines.

These vaccines target various diseases, such as meningitis, pneumonia, and polio. Stakeholders In the market include government immunization programs, preventive healthcare providers, vaccine manufacturers, genomic research centers, academic institutions, private laboratori

Canada Exports of human or animal blood, antisera and other blood fractions, vaccines, toxins to Bahrain was US$269.37 Thousand during 2023, according to the United Nations COMTRADE database on international trade.

Snapshot img

Tetanus Toxoid Vaccine Market Size 2024-2028

The tetanus toxoid vaccine market size is forecast to increase by USD 1.24 billion at a CAGR of 4.5% between 2023 and 2028.

The market is witnessing significant growth due to several key factors. Licensing agreements between vaccine manufacturers and governments or healthcare organizations are driving market expansion. Furthermore, the introduction of new tetanus toxoid vaccines, such as those containing additional antigens, is contributing to market growth. However, the high cost of healthcare, vaccines, and treatments for infectious diseases remains a challenge for the market, particularly in developing countries. To mitigate this, governments and non-profit organizations are implementing initiatives to increase vaccine affordability and accessibility. Overall, the market is expected to continue its growth trajectory in the coming years, with a focus on increasing vaccine accessibility and affordability to combat infectious diseases.

What will be the Size of the Tetanus Toxoid Vaccine Market During the Forecast Period?

Request Free Sample

The market encompasses the production and distribution of vaccines designed to prevent Tetanus and in some cases, Diphtheria. These vaccines are essential medicines In the global public health landscape, protecting against vaccine-preventable diseases. Tetanus, a bacterial infection causing severe muscle stiffness and spasms, can lead to life-threatening complications. The market includes Diphtheria-Tetanus-Pertussis (DTP) and Tetanus-Diphtheria (TD) vaccines, as well as more recent combinations like the Tetanus, Diphtheria, and Pertussis (Tdap) vaccine. Vaccination schedules recommend these vaccines for childhood immunization, asylum seekers, and pregnant women, among others. Tetanus Toxoid, a key component of these vaccines, stimulates the production of immunity against Tetanus.
Vaccine development continues, with ongoing clinical investigations into new formulations and dosage recommendations. Immunogenicity, safety, and efficacy are crucial considerations In the development process. The market's growth is driven by the ongoing commitment to preventing Tetanus and other vaccine-preventable diseases.

How is this Tetanus Toxoid Vaccine Industry segmented and which is the largest segment?

The tetanus toxoid vaccine industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Age Group

  Neonatals
  Adults


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France


  Asia



  Rest of World (ROW)

By Age Group Insights

The neonatals segment is estimated to witness significant growth during the forecast period.

Tetanus is a bacterial infection causing muscle stiffness and spasms, with neonatal tetanus being a particular concern, affecting newborns through contaminated umbilical stumps or nonsterile delivery instruments. Vaccines, including Tetanus Toxoid, Diphtheria-Tetanus-Pertussis (DTaP), and Tetanus and Diphtheria, play a crucial role in preventing tetanus. Vaccine development involves clinical investigation and rigorous testing for efficacy and safety. Hospitals and clinics administer these vaccines, following immunization schedules for children and adults. Vaccines are essential medicines in publicly funded programs, and their availability is critical in reducing disease burden. Booster doses and immunity maintenance are essential for long-term protection. Tetanus toxoid vaccine manufacturing adheres to stringent standards to ensure safety and efficacy.

Vaccines prevent various vaccine-preventable diseases, including diphtheria, pertussis, hepatitis B, poliomyelitis, and tuberculosis. Immunization is a vital public health intervention to protect individuals and communities.

Get a glance at the market report of share of various segments Request Free Sample

The Neonatals segment was valued at USD 3.39 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 44% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

The market in North America holds a significant share due to increased adoption, comprehensive end-user coverage, and the presence of major market players like Pfizer Inc., Merck & Co. Inc., and GlaxoSmithKline Plc. In the US, tetanus cases are rare, with approximately 30 reported annually according to the National Notifiable Disease Surveillance System (NNDSS) of the Centers for Disease Control and Preventio

Canada Exports of human or animal blood, antisera and other blood fractions, vaccines, toxins to Israel was US$1.63 Million during 2022, according to the United Nations COMTRADE database on international trade.

Snapshot img

Influenza Vaccine Market Size 2024-2028

The influenza vaccine market size is forecast to increase by USD 3.76 billion at a CAGR of 8.09% between 2023 and 2028. The market is experiencing significant growth due to the increasing prevalence and incidence of severe influenza cases, particularly among children. The Global Influenza Program's emphasis on vaccination as a preventative measure is driving market expansion. Combination vaccines, which offer protection against multiple strains of the virus, are gaining popularity due to their convenience and effectiveness. Furthermore, the development of mRNA vaccines, which utilize advanced technology to produce a more potent immune response, is a promising trend in the market. The market for Influenza vaccines encompasses various types, including inactivated vaccines, live attenuated vaccines, quadrivalent vaccines, mono vaccine, trivalent vaccines, pnemucoccol vaccine, pediatric vaccines, and adult vaccines. Despite these advancements, challenges persist, including the difficulty in diagnosing influenza due to its non-specific symptoms and the need for annual revaccination to maintain immunity. Overall, the market is poised for continued growth as the demand for effective vaccines to prevent the spread of influenza remains high.

Market Analysis

Request Free Sample

The market is a significant sector within the global healthcare industry, with a continuous demand due to the seasonal nature of the influenza virus and the ongoing threat of potential pandemics. This market caters to various demographics, including children and adults, through various vaccine types and administration methods. Seasonal influenza vaccines are the primary focus of the market, with two main types: inactivated vaccines and live attenuated vaccines. Inactivated vaccines, also known as flu shots, use killed viruses to stimulate an immune response, while live attenuated vaccines, or nasal sprays, use weakened live viruses.

Furthermore, both types offer protection against the three or four strains of the virus predicted to cause the most significant impact during a season. Quadrivalent vaccines, a more recent addition to the market, protect against an additional B strain, broadening the scope of coverage and potentially reducing the risk of infection. Trivalent vaccines, which protect against three strains, continue to be available and are often used in mass vaccination programs. The pediatric segment of the market is of significant importance due to the vulnerability of children to severe influenza cases. The global influenza program, a collaborative effort between the World Health Organization (WHO) and various national health organizations, plays a crucial role in ensuring the availability of vaccines for children and other at-risk populations.

In addition, combination vaccines, which offer protection against influenza and other diseases, are gaining popularity in the market due to their convenience and potential for reducing the number of vaccinations required. MRNA vaccines, a newer technology, have shown promising results in clinical trials and may become a significant player in the market in the coming years. The market is influenced by several factors, including the severity of seasonal epidemics, the availability and affordability of vaccines, and the public's perception of vaccine efficacy and safety. Hospital and retail pharmacies serve as essential distribution channels for these vaccines, ensuring they reach the end consumer in a timely and convenient manner.

Furthermore, swine flu vaccines, while not a regular component of the seasonal the market, are produced and distributed in response to outbreaks or pandemics. The production and distribution of these vaccines require a rapid response and significant resources, highlighting the importance of a strong global influenza program and the flexibility of vaccine manufacturers. In conclusion, the market is a dynamic and evolving sector within the healthcare industry. With ongoing research and development, the market continues to offer new solutions to protect against the influenza virus, ensuring public health and safety.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Distribution Channel

  Hospitals and pharmacies
  Government and institutional
  Others


Type

  Live attenuated influenza vaccines
  Recombinant influenza vaccines


Geography

  North America

    Canada
    US


  Europe

    UK


  Asia

    China
    India


  Rest of World (ROW)

By Distribution Channel Insights

The hospitals and pharmacies segment is estimated to witness significant growth during the forecast period.The market in the US is categorized by distributio

In 2022, there were three reported cases of measles in Canada, compared to over two thousand cases in 1995. This statistic shows the number of reported cases of measles in Canada from 1930 to 2022.

Canada Imports from Cameroon of Human or Animal Blood, Antisera and Other Blood Fractions, Vaccines, Toxins was US$37 during 2023, according to the United Nations COMTRADE database on international trade.

Nicaragua Exports of human or animal blood, antisera and other blood fractions, vaccines, toxins to Canada was US$45 Thousand during 2015, according to the United Nations COMTRADE database on international trade.